AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04710121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
Study NCT05074875 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and Patient Reported Outcomes (PROs)
Description: * EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~* St. George's Respiratory Questionnaire (SGRQ)~* Impact of Events Scale Revised (IES-R)~* Generalized Anxiety Disorder 7-Item (GAD-7)~* Patient Health Questionnaire (PHQ-9)
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)
Description: If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
Study NCT05074875 — intervention group
Intervention type: GENETIC
Intervention: Blood Samples for Biomarkers
Description: Venous blood will be collected using pre-labeled tubes.
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High Resolution Computed Tomography
Description: Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Exam and Vital Signs
Description: A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested.
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Medical Research Council Sum Score
Description: The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand Grip Strength
Description: Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusing Capacity of Carbon Monoxide
Description: The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6 Minute Walk Test
Description: The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test.
Study NCT05074875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sit to Stand (STS) Measurement
Description: The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
Study NCT06029764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended one-level interbody fusion
Description: For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
Study NCT06238414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early psychotherapeutic intervention
Description: The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
Study NCT05016518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I (Propofol group)
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
Study NCT05016518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (Remimazolam group)
Description: Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
Study NCT04929275 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enhanced recovery program
Description: 12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
Study NCT06043466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-targeted CAR-T cells
Description: Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study NCT04813523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
Study NCT05866913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve slippage.
Description: Sciatic nerve slippage.
Study NCT05866913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive stretching of the hamstring muscles.
Description: Passive stretching of the hamstring muscles.
Study NCT05866913 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: passive shoulder mobilization.
Description: passive shoulder mobilization.
Study NCT06293833 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT scan
Description: Participants get an annual low-dose CT scan in UZA
Study NCT06293833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Smoking cessation campagnes
Study NCT05122481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C (also known as ascorbic acid and ascorbate) is a vitamin found in various foods and sold as a dietary supplement.Vitamin C is a water-soluble vitamin, with dietary excesses not absorbed, and excesses in the blood rapidly excreted in the urine, so it exhibits remarkably low acute toxicity. More than one gram may cause indigestion, flatulence and stomach pain.
Study NCT06227169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JJ-COPES Training
Description: • The JJ-COPES training is derived from an empirically supported CBT manual designed for outpatient treatment of suicidal adolescents. JJ-COPES training focuses on teaching 4 primary treatment strategies plus a caregiver session to community-based clinicians.
Study NCT04753034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TER-101
Description: Active Comparator
Study NCT04753034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo Comparator
Study NCT04763720 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dyadic Developmental Psychotherapy
Description: DDP involves approximately twenty sessions with the family, conducted by a trained DDP therapist. DDP is developed to treat trauma-related and attachment difficulties. DDP is not a manualized treatment but involves using a set of core communication techniques (termed PACE; Playfulness, Acceptance, Curiosity and Empathy).
Study NCT06458348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local opera appreciating and Medical gymnastics training
Description: To construct a local opera viewing combined medical gymnastics training program for elderly patients with post-stroke cognitive impairment, and to explore its feasibility, acceptability and safety.
Study NCT05673031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-HA-DOTATATE PET/CT imaging
Description: Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~* The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results.
Study NCT05907525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Study NCT05907525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% propofol
Description: To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Study NCT04886414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based monitoring
Description: Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.
Study NCT04886414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation monitoring
Description: Oxygen saturation will be monitored and recorded at regular intervals.
Study NCT04886414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer
Description: Alcohol-based hand sanitizer will be distributed to subjects.
Study NCT04733924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous extract of roots plus leaves of Withania somnifera 125 mg
Description: One capsule before breakfast for 84 days
Study NCT04733924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous extract of roots plus leaves of Withania somnifera 250 mg
Description: One capsule before breakfast for 84 days
Study NCT04733924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: One capsule before breakfast for 84 days
Study NCT05474495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
Study NCT05474495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transverse abdominas strength training
Description: Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
Study NCT05414214 — intervention group
Intervention type: PROCEDURE
Intervention: Thyromental Height Test
Description: Thyromental Height Test (TMHT) : will be measured while a patient is lying supine with the head and neck are maintained in a neutral position using a pillow under the head. By using a digital depth gauge, the TMH is the vertical distance measured between the anterior border of the thyroid cartilage directly on the thyroid notch and the anterior border of the mentum.
Study NCT05414214 — intervention group
Intervention type: PROCEDURE
Intervention: Sternomental displacement
Description: Sternomental displacement (SMDD): While the patient is sitting with the head in a neutral position, SMD-neutral will be measured using a tape as the distance between upper borders of the manubrium sterni and the mentum. The SMD-extension will then be measured in the same way with the head extended on the neck. The difference between SMD-extension and SMD-neutral will then be calculated as SMDD.
Study NCT05414214 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: patients will be pre-oxygenated with 100% oxygen for 3 minutes, anesthesia will be then induced intravenously using fentanyl 2 μg/kg, propofol 1 -1.5 mg/kg, and succinylcholine 1 mg/kg lean body weight. Mask ventilation will be maintained till complete muscle relaxation guided by a peripheral nerve stimulator. Using Macintosh laryngoscopy, an anesthetist who has at least three years experience and who will be blinded to the preoperative tests' results, determined the best laryngeal view by using Cormack-Lehane (CL) grading system from I-IV. External neck manipulation will be used when needed to obtain the best laryngoscopic view. Endotracheal intubation will then be accomplished. The number and duration of intubation attempts will be recorded.
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 1 low dose
Description: Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 2 low dose
Description: Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 1 high dose
Description: Participants will receive single intranasal injection of H3N2 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec component 2 high dose
Description: Participants will receive single intranasal injection of H1N1pdm09 recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec low dose
Description: Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Corfluvec high dose
Description: Participants will receive two intranasal injections of recombinant attenuated influenza vector with modified NS gene coding for the N protein fragment of SARS-CoV-2 tree weeks apart (H3N2 →H1N1pdm09)
Study NCT05696067 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive two intranasal injections of placebo three weeks apart
Study NCT06424808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consolidating content on a single website and providing access to it via QR codes in a brochure format
Description: The group assigned to the experimental group will receive information in the same manner as current patients do, with the addition of receiving a brochure once when moving to a general ward after surgery. Afterward, they are free to use the brochure. The control group will receive information only in the manner currently provided to patients.
Study NCT05423977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZV0203
Description: Participants will be allocated to one of the following dose groups: 0.3, 0.6, 1.2, 1.8, 2.7 and 3.6 mg/kg, and receive a treatment of ZV0203-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
Study NCT06032663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Patients that participate in the current study will have an extra PET-MRI scan, which will expose them to a small amount (4 - 6 mSv) of extra radiation.
Study NCT06429865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cytosponge
Description: Use of cytosponge as a tool to patients who need surveillance after endoscopic submucosal dissection for esophageal squamous cell carcinoma
Study NCT06422039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（D）Tablets
Description: One HRS-7535（D）Tablet is administered to healthy subjects.
Study NCT06422039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535（C）Tablets
Description: Two HRS-7535（C）Tablets is administered to healthy subjects.
Study NCT06073288 — intervention group
Intervention type: OTHER
Intervention: Surgical specimens of CD and no-IBD patients
Description: Specimens of CD patients and patients without IBD-related disease (ex. diverticulitis) will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
Study NCT06007976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia® Trident
Description: Low-level laser therapy
Study NCT05572203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intrinsically labelled protein
Description: It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
Study NCT05572203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intrinsically labelled protein
Description: It is a protein drink that includes Intrinsically labelled Casein ( from Arla Foods), 13C/2H-labelled Spirulina (from CK Isotopes), and 13C/2H-labelled amino acids (from CK Isotopes)
Study NCT04745728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1mg/kg/d p.o.which will be tapered after 2 months and discontinued over a 6-12 month period.
Study NCT04745728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1-2mg/kg/d p.o. with a target accumulated dose of 12g.
Study NCT04745728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000mg I.V. on D1 and at 6 month. After 6 month, in patients with response but not complete remission, Rituximab could be stopped or repeated with a 6 month-interval (12 month, 18 month, 24 month) until complete remission. Rituximab 1000mg I.V. will be repeated on the 15th day of each Rituximab infusion if CD19+ B cell count>5/ul.
Study NCT05335616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Hypothetical guideline regarding the indications and treatment steps involved in dental restoration repair.
Study NCT05335616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment fee item
Description: Arrangement of a hypothetical treatment fee item which can be charged in addition to the actual repair restoration.
Study NCT06095908 — intervention group
Intervention type: DRUG
Intervention: Bupivacain
Description: Bupivacain administered with two different ways to the patients, postoperative pain recorded